Michael Hitsman
Family Medicine · Vinita, OKNPI 1306387907
Payments from drug & device makers
Across 188 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$460
- GSK$338
- Pfizer$235
- AstraZeneca$233
- Johnson & Johnson$225
- Boehringer Ingelheim$224
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,970100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $460 |
| GSK | 26 | $338 |
| Pfizer | 15 | $235 |
| AstraZeneca | 17 | $233 |
| Johnson & Johnson | 16 | $225 |
| Boehringer Ingelheim | 15 | $224 |
| Amgen | 14 | $214 |
| Lilly USA, LLC | 10 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $133 |
| Bayer | 7 | $118 |
| Novartis | 6 | $88 |
| Merck | 5 | $83 |
| Novo Nordisk | 6 | $80 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $77 |
| Amarin Pharma, Inc. | 4 | $62 |
| Eisai Inc. | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Exact Sciences | 2 | $40 |
| Biogen | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$2,977 in reported general payments places this provider in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 286 | $86,814 |
| TrulicityDulaglutide | 21 | $19,765 |
| XareltoRivaroxaban | 67 | $19,635 |
| MyrbetriqMirabegron | 73 | $17,660 |
| JardianceEmpagliflozin | 43 | $13,680 |
| RestasisCyclosporine | 16 | $9,951 |
| Pantoprazole Sodium | 173 | $8,211 |
| JanuviaSitagliptin Phosphate | 25 | $7,429 |
| Spiriva RespimatTiotropium Bromide | 13 | $7,122 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,614 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $6,261 |
| Cinacalcet Hcl | 18 | $5,878 |
| GemtesaVibegron | 22 | $5,450 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $5,303 |
| SantylCollagenase Clostridium Hist. | 12 | $4,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $235 | $86,814286 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $144 | $22,422116 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $224 | $20,80256 claims |
| Johnson & JohnsonXarelto | $225 | $19,63567 claims |
| AbbVieRestasis, Lumigan, Combigan | $460 | $15,87640 claims |
| GSKBreo Ellipta, Anoro Ellipta | $338 | $12,87531 claims |
| MerckJanuvia, Dulera | $83 | $12,10838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Vinita
- Mickey TyrrellVinita$22K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.